Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SMD Rise Public Company Limited (SMD100.BK)
Nonthaburi, TH
SMD Rise Public Company Limited, established in 1998 and headquartered in Nonthaburi, Thailand, focuses on the import and supply of a wide range of medical devices, equipment, and associated supplies. The company serves the Thai healthcare sector, including private hospitals, clinics, and the general public. In addition to product distribution, SMD Rise offers various services such as sleep diagnostic testing, as well as providing flexible medical equipment acquisition solutions through rental, hire purchase, and leasing arrangements. The company also extends its services to include wellness equipment. Its comprehensive product portfolio encompasses radiology-related items and other comparable medical products. It is important to note that the entity currently known as SaintMed Public Company Limited will officially change its name to SMD Rise Public Company Limited in January 2025.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.34% | -8.09% | -22.84% | -34.21% | -54.71% | -46.12% | -68.43% | -79.84% | -81.78% | -81.78% | -81.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Distribution: +5.6%+10.0% ★ Q1'26: -3.9% (vs Q2'24)
-
EPS growth Medical - Distribution: +4.9%-85.4% Q1'26: -692.9% (vs Q2'24)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-17.5% Q1'26: +33.9% (vs Q2'24)
-
EBIT margin Medical - Distribution: +3.0%+2.7% Q1'26: -16.4% (vs Q2'24)
-
ROIC Medical - Distribution: +5.7%+1.5% Q1'26: -12.5% (vs Q2'24)
-
Share dilution Medical - Distribution: +0.0%-7.2% ★ Q1'26: -0.7% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×4.65× Q1'26: -6.41× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
1.62B
1.62B – 1.62B
|
1.65B
1.65B – 1.65B
+1.6% YoY
|
1.68B
1.68B – 1.68B
+2.0% YoY
|
| EBITDA |
330.84M
330.84M – 330.84M
|
336.14M
336.14M – 336.14M
+1.6% YoY
|
342.88M
342.88M – 342.88M
+2.0% YoY
|
| EBIT |
280.68M
280.68M – 280.68M
|
285.18M
285.18M – 285.18M
+1.6% YoY
|
290.89M
290.89M – 290.89M
+2.0% YoY
|
| Net Income |
317.74M
317.74M – 317.74M
|
270.82M
270.82M – 270.82M
-14.8% YoY
|
334.80M
334.80M – 334.80M
+23.6% YoY
|
| SGA |
334.14M
334.14M – 334.14M
|
339.50M
339.50M – 339.50M
+1.6% YoY
|
346.31M
346.31M – 346.31M
+2.0% YoY
|
| EPS |
1.42
1.42 – 1.42
|
1.21
1.21 – 1.21
-14.8% YoY
|
1.50
1.50 – 1.50
+23.6% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kittathum Nguansamarng | Chief of HR and IT, Deputy CEO of Customer Relations and Business Dev & Director | — | male |
| Pimlavee JanJai | Chief Accountant | — | female |
| Prapassorn Patamapinun | Chief Financial Officer | — | female |
| Rhamon Vasusuttikulkant | Co-Founder, Chief Sales and Marketing Officer & Director | — | female |
| Sorajja Boonprasit | Co-Founder, Deputy CEO of Customer Relations and Business Dev, COO & Director | — | female |
| Taveesak Boonprasit | Co-Founder, Deputy CEO of Customer Relations and Business Dev, Chief Service Officer & Director | — | male |
| Viroje Vasusuttikulkant | Co-Founder, Company Secretary, CEO & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SMD100.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
